Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …

Abstract The European Group for Blood and Marrow Transplantation (EBMT) risk score
provides a simple tool to assess instantly chances and risks of hematopoietic SCT (HSCT) …

Background Randomized trials have shown that the transplantation of filgrastim-mobilized
peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but …

Background In this study we tried to achieve successful transplantation in patients with acute
leukemia with the use of hematopoietic stem cells from donors who shared only one HLA …

The National Marrow Donor Program (NMDP) maintains a registry of approximately 4 million
volunteer unrelated donors for patients in need of a stem cell transplant. When several …

The potential benefits of unrelated donor marrow transplantation are offset by the
immunologic complications of graft-versus-host disease (GVHD) and infection. Therefore …

Purpose Patients with acute leukemia refractory to induction or reinduction chemotherapy
have poor prognoses if they do not undergo hematopoietic stem-cell transplantation (HSCT) …

Although improvement in outcomes has occurred in younger adults with acute myeloid
leukemia (AML) during the past 4 decades, progress in older adults has been much less …

Graft failure may contribute to increased morbidity and mortality after allogeneic
hematopoietic SCT (allo-HSCT). Here, we present risk factors for graft failure in all first allo …

Background Umbilical-cord blood from unrelated donors who are not HLA-identical with the
recipients can restore hematopoiesis after myeloablative therapy in children. We studied the …